| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; CHUN-JEN LIU ; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 45 | 42 | |
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; CHUN-JEN LIU ; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 49 | 43 | |
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | CHUN-JEN LIU ; Chang J.; PO-HUANG LEE ; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO ; Yang S.-S.; Yang M.-D.; Yu M.-C.; REY-HENG HU ; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN | World Journal of Gastroenterology | 52 | 48 | |
| 2016 | All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study | JIA-HORNG KAO ; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S. | Liver International | 22 | 25 | |
| 2014 | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study | Manns M.; Pol S.; Jacobson I.M.; Marcellin P.; Gordon S.C.; Peng C.-Y.; Chang T.-T.; Everson G.T.; Heo J.; Gerken G.; Yoffe B.; Towner W.J.; Bourliere M.; Metivier S.; Chu C.-J.; Sievert W.; Bronowicki J.-P.; Thabut D.; Lee Y.-J.; JIA-HORNG KAO ; McPhee F.; Kopit J.; Mendez P.; Linaberry M.; Hughes E.; Noviello S. | The Lancet | 298 | 275 | |
| 2008 | Baicalein attenuates intimal hyperplasia after rat carotid balloon injury through arresting cell-cycle progression and inhibiting ERK, Akt, and NF-κB activity in vascular smooth-muscle cells | Peng C.-Y.; Pan S.-L.; Huang Y.-W.; JIH-HWA GUH ; Chang Y.-L.; Teng C.-M. | Naunyn-Schmiedeberg's Archives of Pharmacology | 40 | 38 | |
| 2007 | CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression | Wang S.-W.; Pan S.-L.; Peng C.-Y.; Huang D.-Y.; Tsai A.-C.; Chang Y.-L.; JIH-HWA GUH ; Kuo S.-C.; Lee K.-H.; Teng C.-M. | Cancer Letters | 23 | 22 | |
| 2018 | Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan | CHEN-HUA LIU ; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 38 | 40 | |
| 2016 | Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis | JIA-HORNG KAO ; Jensen D.M.; Manns M.P.; Jacobson I.; Kumada H.; Toyota J.; Heo J.; Yoffe B.; Sievert W.; Bessone F.; Peng C.-Y.; Roberts S.K.; Lee Y.-J.; Bhore R.; Mendez P.; Hughes E.; Noviello S. | Liver International | 12 | 11 | |
| 2017 | Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1 | JIA-HORNG KAO ; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. | Journal of Gastroenterology and Hepatology (Australia) | 16 | 12 | |
| 2011 | Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways | Chen P.-H.; Peng C.-Y.; Pai H.-C.; Teng C.-M.; Chen C.-C.; CHIA-RON YANG | Journal of Nutritional Biochemistry | 15 | 12 | |
| 2018 | Development and Psychometric Properties of the Taiwan Odd–Even Number Sequencing Test: A Nonalphabetic Measure of Working Memory | Chen Y.-T.; Peng C.-Y.; Hua M.-S.; CHEN-CHUNG LIU ; Chen H.-Y.; HAI-GWO HWU | Assessment | 2 | 2 | |
| 2016 | Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan | Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU ; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO | Hepatology International | 3 | 3 | |
| 2019 | Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions | Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; CHEN-HUA LIU ; Huang C.-F.; Su C.-W.; Huang J.-F.; CHUN-JEN LIU ; JIA-HORNG KAO ; Chuang W.-L.; PEI-JER CHEN ; DING-SHINN CHEN | Journal of the Formosan Medical Association | 9 | 8 | |
| 2016 | Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues | Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; TUNG-HUNG SU ; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO | Hepatology Research | 2 | 0 | |
| 2018 | Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV | CHUN-JEN LIU ; Chuang W.-L.; Sheen I.-S.; Wang H.-Y.; Chen C.-Y.; Tseng K.-C.; Chang T.-T.; Massetto B.; Yang J.C.; Yun C.; Knox S.J.; Osinusi A.; Camus G.; Jiang D.; Brainard D.M.; McHutchison J.G.; Hu T.-H.; Hsu Y.-C.; Lo G.-H.; Chu C.-J.; Chen J.-J.; Peng C.-Y.; Chien R.-N.; PEI-JER CHEN | Gastroenterology | 82 | 79 | |
| 2020 | Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis | CHEN-HUA LIU ; Peng C.-Y.; YU-JEN FANG ; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU ; CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Scientific Reports | 5 | 5 | |
| 2021 | Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan | Cheng P.-N.; Chen C.-Y.; Yu M.-L.; Lin C.-C.; Lin C.-Y.; Peng C.-Y.; Tseng K.-C.; Lo C.-C.; Tseng I.-H.; CHUN-JEN LIU | Journal of Microbiology, Immunology and Infection | 4 | 3 | |
| 2022 | Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial | Cheng P.-N.; CHUN-JEN LIU ; Chen C.-Y.; Tseng K.-C.; Lo C.-C.; Peng C.-Y.; Lin C.-L.; Chiu H.-C.; Chiu Y.-C.; PEI-JER CHEN | Clinical Gastroenterology and Hepatology | 4 | 4 | |
| 2011 | Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease | Keating G.M.; Buti M.; Gadano A.; JIA-HORNG KAO ; Lee C.-M.; Peng C.-Y.; Schiff E.R.; Tanwandee T. | Drugs | 19 | 17 |
